Gilead Sciences, Inc.
GILD
Updated: 22/09/2026, 14:43:44
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
No summaries found.
The original document can be viewed now. Detailed facts and exposure relationships will appear after the separate extraction job completes.
- Share price
- $150.56
- Market cap
- $186.93B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Daniel O'Day
- Employees
- 17,000
- IPO date
- 22/01/1992
- Beta
- 0.35
- Last dividend
- $0.00
- Day range
- $150.52 – $152.12
- 52-week range
- $108.46 – $157.29
- 1-day performance
- 0.30%
- 1-year performance
- 38.82%
- Current drawdown (1Y)
- -4.28%
- CIK
- 0000882095
- CUSIP
- 375558103
- ISIN
- US3755581036
- Created
- 07/12/2025, 04:13:56
- Last update
- 22/09/2026, 14:43:44
Track Gilead Sciences, Inc. with an AI analyst
See which prediction-market events move GILD, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
Zacks Investment Research • STOCK • 11/06/2026, 16:26:14
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 09/06/2026, 22:12:11
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
Zacks Investment Research • STOCK • 09/06/2026, 18:36:09
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Business Wire • STOCK • 08/06/2026, 18:35:00
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
Business Wire • STOCK • 05/06/2026, 05:00:00
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
GlobeNewsWire • STOCK • 04/06/2026, 18:15:00
GILD Reports Positive Results From Late-Stage Liver Disease Study
Zacks Investment Research • STOCK • 03/06/2026, 14:21:07
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research • STOCK • 03/06/2026, 12:00:35
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome
Benzinga • STOCK • 02/06/2026, 15:47:38
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
Business Wire • STOCK • 27/05/2026, 04:00:00
GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy
Zacks Investment Research • STOCK • 25/05/2026, 14:01:19
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference
MarketBeat • STOCK • 24/05/2026, 11:04:21